These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1982707)

  • 1. The use of sulphasalazine as a disease modifying antirheumatic drug.
    Porter DR; Capell HA
    Baillieres Clin Rheumatol; 1990 Dec; 4(3):535-51. PubMed ID: 1982707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-modifying antirheumatic drugs: gold, penicillamine, antimalarials, and sulfasalazine.
    Smith MD
    Curr Opin Rheumatol; 1990 Jun; 2(3):489-96. PubMed ID: 1975503
    [No Abstract]   [Full Text] [Related]  

  • 3. [Sulfasalazine in rheumatology].
    Nurchis P; Garau P; Pala MR; Uras L; Saviano M; Mathieu A
    Ann Ital Med Int; 1990; 5(3 Pt 1):186-91. PubMed ID: 1981136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-modifying antirheumatic drugs: gold, penicillamine, antimalarials, and sulfasalazine.
    Smith MD
    Curr Opin Rheumatol; 1989 Jun; 1(1):74-9. PubMed ID: 2577111
    [No Abstract]   [Full Text] [Related]  

  • 5. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium.
    Choy EH; Scott DL; Kingsley GH; Williams P; Wojtulewski J; Papasavvas G; Henderson E; Macfarlane D; Erhardt C; Young A; Plant MJ; Panayi GS
    Clin Exp Rheumatol; 2002; 20(3):351-8. PubMed ID: 12102471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical studies with salazopyrine--consequences and perspectives].
    Zeidler H
    Z Rheumatol; 1987; 46(2):59-66. PubMed ID: 2885985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Slow-acting antirheumatic agents].
    van de Putte LB; van Riel PL
    Ned Tijdschr Geneeskd; 1989 Apr; 133(14):708-13. PubMed ID: 2566127
    [No Abstract]   [Full Text] [Related]  

  • 8. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulphasalazine in the treatment of children with chronic arthritis.
    Huang JL; Chen LC
    Clin Rheumatol; 1998; 17(5):359-63. PubMed ID: 9805178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.
    Rains CP; Noble S; Faulds D
    Drugs; 1995 Jul; 50(1):137-56. PubMed ID: 7588084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine.
    Conaghan PG; Brooks P
    Curr Opin Rheumatol; 1995 May; 7(3):167-73. PubMed ID: 7612407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfasalazine for ankylosing spondylitis.
    Chen J; Liu C
    Cochrane Database Syst Rev; 2005 Apr; (2):CD004800. PubMed ID: 15846731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.
    Capell HA; Madhok R; Porter DR; Munro RA; McInnes IB; Hunter JA; Steven M; Zoma A; Morrison E; Sambrook M; Wui Poon F; Hampson R; McDonald F; Tierney A; Henderson N; Ford I
    Ann Rheum Dis; 2007 Feb; 66(2):235-41. PubMed ID: 16926184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components.
    Dougados M; Combe B; Cantagrel A; Goupille P; Olive P; Schattenkirchner M; Meusser S; Paimela L; Rau R; Zeidler H; Leirisalo-Repo M; Peldan K
    Ann Rheum Dis; 1999 Apr; 58(4):220-5. PubMed ID: 10364900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and D-penicillamine.
    Conaghan PG; Brooks P
    Curr Opin Rheumatol; 1993 May; 5(3):276-81. PubMed ID: 8099805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
    Simon LS
    Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying effect of etanercept versus sulphasalazine on spinal mobility in patients with ankylosing spondylitis.
    Hendrix S; Koenig A; Li W; Singh A
    J Int Med Res; 2013 Oct; 41(5):1606-11. PubMed ID: 23975857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study.
    Farr M; Kitas GD; Waterhouse L; Jubb R; Felix-Davies D; Bacon PA
    Br J Rheumatol; 1990 Feb; 29(1):46-9. PubMed ID: 1968355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulphasalazine in rheumatic diseases.
    Dougados M
    Agents Actions Suppl; 1993; 44():197-201. PubMed ID: 8103962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity.
    Linares V; Alonso V; Domingo JL
    Expert Opin Drug Saf; 2011 Mar; 10(2):253-63. PubMed ID: 21219240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.